Trial Profile
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, data from this studywill be presented at the 2017 San Antonio Breast Cancer Symposium.
- 23 Jun 2017 Status changed from recruiting to completed.